reviewTop 1% cited
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
European Urology · 2020 · Vol. 79(2) · pp. 263–282
Philip Cornford✉Roderick C.N. van den Bergh(St. Antonius Ziekenhuis)Erik BriersThomas Van den Broeck(KU Leuven)Marcus Cumberbatch(University of Sheffield)Maria De Santis(Charité - Universitätsmedizin Berlin)Stefano Fanti(Policlinico S.Orsola-Malpighi)Nicola Fossati(IRCCS Ospedale San Raffaele)Giorgio Gandaglia(IRCCS Ospedale San Raffaele)Silke Gillessen(University of Manchester)Nikolaos Grivas(The Netherlands Cancer Institute)Jeremy Grummet(Monash University)Ann Henry(St James's University Hospital)Theodorus van der Kwast(Erasmus MC)Thomas Lam(University of Aberdeen)Michael Lardas(Metropolitan Hospital)Matthew Liew(Wrightington, Wigan and Leigh NHS Foundation Trust)Malcolm D. Mason(Cardiff University)Lisa Moris(KU Leuven)Daniela E. Oprea‐Lager(Amsterdam University Medical Centers)Henk G. van der Poel(The Netherlands Cancer Institute)Olivier RouvièreIvo G. SchootsDerya TilkiThomas Wiegel(University Hospital Ulm)Peter-Paul Willemse(University Medical Center Utrecht)Nicolas Mottet(Centre Hospitalier Universitaire de Saint-Étienne)
Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentHormonal and reproductive studiesMedicineProstate cancerProstatectomyRadiation therapyAndrogen deprivation therapyGuidelineOncologyCancerRadiation oncologistInternal medicine
MeSH terms
HumansMaleNeoplasm MetastasisNeoplasm Recurrence, LocalProstatic Neoplasms
Citations
1,110
FWCI
97.34
field-weighted impact
References
192
Percentile
100%
vs. same field & year
Citations per year
References
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
European Journal of Cancer · 2008 · 28,935 citations
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
European Urology · 2014 · 802 citations
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
The Lancet Oncology · 2015 · 1,334 citations
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
International Journal of Radiation Oncology*Biology*Physics · 2006 · 2,705 citations
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
BMJ · 2008 · 21,184 citations
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
Journal of Clinical Oncology · 2008 · 2,225 citations
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
The Lancet Oncology · 2012 · 1,374 citations
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
European Urology · 2016 · 1,439 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.